Sapena R, Morin D, Zini R, Tillement J P
Department of Pharmacology, Faculty of Medicine of Paris XII, Creteil, France.
Drugs Exp Clin Res. 1994;20(3):93-102.
The influence of chronic administration of desipramine (16 mg/kg per day for 8 days) or citalopram (1 mg/kg per day for 8 days) on the serotonergic and noradrenergic stimulations of phosphoinositide hydrolysis and cyclic AMP formation was investigated in rat cerebral cortical slices. This was done by means of a prelabelling method allowing the simultaneous measurement of the accumulations of (3H) inositol phosphates ((3H)IP) and of (14C) cyclic AMP. Our results show that neither of the two drugs altered the inhibition of adenylate cyclase activity induced by serotonin1 (5-HT1) receptor agonists nor did they alter 5-HT1A and 5-HT1B receptor densities. Similarly they did not modify the stimulation of the inositol phosphate metabolism induced by 5-HT or norepinephrine (NE). Desipramine treatment decreased both beta-adrenoceptor-elicited cyclic AMP accumulation (-37%) and beta-adrenoceptor density (-29%), whereas citalopram was without effect. These results reinforce the idea that the ability of antidepressants to decrease the activity of the beta-adrenoceptor-adenylate cyclase complex is not common to all antidepressants, and provide no evidence for the involvement of 5-HT1A and/or 5-HT1B in the mechanism of action of these drugs.
在大鼠大脑皮质切片中,研究了慢性给予地昔帕明(每天16毫克/千克,持续8天)或西酞普兰(每天1毫克/千克,持续8天)对磷酸肌醇水解和环磷酸腺苷形成的5-羟色胺能及去甲肾上腺素能刺激的影响。这是通过一种预标记方法完成的,该方法可同时测量(3H)肌醇磷酸((3H)IP)和(14C)环磷酸腺苷的积累。我们的结果表明,这两种药物均未改变5-羟色胺1(5-HT1)受体激动剂诱导的腺苷酸环化酶活性抑制,也未改变5-HT1A和5-HT1B受体密度。同样,它们也未改变5-羟色胺(5-HT)或去甲肾上腺素(NE)诱导的肌醇磷酸代谢刺激。地昔帕明治疗降低了β-肾上腺素能受体引发的环磷酸腺苷积累(-37%)和β-肾上腺素能受体密度(-29%),而西酞普兰则无此作用。这些结果强化了以下观点:降低β-肾上腺素能受体-腺苷酸环化酶复合物活性的能力并非所有抗抑郁药所共有,且没有证据表明5-HT1A和/或5-HT1B参与了这些药物的作用机制。